MicroRNA‑126 inhibits proliferation and metastasis in prostate cancer via regulation of ADAM9

Hua,Yibo; Liang,Chao; Miao,Chenkui; Wang,Shangqian; Su,Shifeng; Shao,Pengfei; Liu,Bianjiang; Bao,Meiling; Zhu,Jundong; Xu,Aiming; Zhang,Jianzhong; Li,Jie; Wang,Zengjun

doi:10.3892/ol.2018.8528

MicroRNA‑126 inhibits proliferation and metastasis in prostate cancer via regulation of ADAM9

Authors:
- Yibo Hua
- Chao Liang
- Chenkui Miao
- Shangqian Wang
- Shifeng Su
- Pengfei Shao
- Bianjiang Liu
- Meiling Bao
- Jundong Zhu
- Aiming Xu
- Jianzhong Zhang
- Jie Li
- Zengjun Wang
View Affiliations

Affiliations: Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China, Department of Pathology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China
Published online on: April 18, 2018 https://doi.org/10.3892/ol.2018.8528
Pages: 9051-9060
Copyright: © Hua et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aberrant expression of microRNAs (miRs) has been identified to serve a crucial role in tumor progression. The present study aimed to evaluate the role of miR‑126 in human prostate cancer (PCa). Firstly, miR‑126 expression in prostate cancer tissues and cell lines was analyzed. A luciferase reporter assay and a rescue assay were performed, which identified ADAM metalloproteinase domain 9 (ADAM9) as the target gene of miR‑126. Subsequently, Kaplan‑Meier and log‑rank analyses were used to investigate the association between ADAM9 expression and PCa prognosis. The results revealed that miR‑126 expression was significantly downregulated in PCa tissues and cell lines. miR‑126 overexpression was demonstrated to reduce PCa cell proliferation and metastasis, and to reverse the epithelial‑mesenchymal transition process in vitro. In addition, as the target gene of miR‑126, the upregulation of ADAM9 reestablished cell functions, including cell proliferation, migration and invasion. Patients with high ADAM9 expression levels exhibited a shorter biochemical recurrence‑free survival time. In summary, miR‑126 serves a role in the proliferation and metastasis of PCa cells, indicating that miR‑126 and ADAM9 may represent potential biomarkers in the progression of advanced PCa, in addition to therapeutic targets.

View Figures

View References

1	Yamamoto S, Kawakami S, Yonese J, Fujii Y, Urakami S, Masuda H, Numao N, Ishikawa Y, Kohno A and Fukui I: Long-term oncological outcome and risk stratification in men with high-risk prostate cancer treated with radical prostatectomy. Jpn J Clin Oncol. 42:541–547. 2012. View Article : Google Scholar : PubMed/NCBI
2	Peyromaure EM, Mao K, Sun Y, Xia S, Jiang N, Zhang S, Wang G, Liu Z and Debré B: A comparative study of prostate cancer detection and management in China and in France. Can J Urol. 16:4472–4477. 2009.PubMed/NCBI
3	Walz J, Gallina A, Saad F, Montorsi F, Perrotte P, Shariat SF, Jeldres C, Graefen M, Bénard F, McCormack M, et al: A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol. 25:3576–3581. 2007. View Article : Google Scholar : PubMed/NCBI
4	Hoang DT, Iczkowski KA, Kilari D, See W and Nevalainen MT: Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles. Oncotarget. 8:3724–3745. 2017. View Article : Google Scholar : PubMed/NCBI
5	Nana-Sinkam SP and Croce CM: Clinical applications for microRNAs in cancer. Clin Pharmacol Ther. 93:98–104. 2013. View Article : Google Scholar : PubMed/NCBI
6	Farazi TA, Hoell JI, Morozov P and Tuschl T: MicroRNAs in human cancer. Adv Exp Med Biol. 774:1–20. 2013. View Article : Google Scholar : PubMed/NCBI
7	Baer C, Claus R and Plass C: Genome-wide epigenetic regulation of miRNAs in cancer. Cancer Res. 73:473–477. 2013. View Article : Google Scholar : PubMed/NCBI
8	Ebrahimi F, Gopalan V, Smith RA and Lam AK: miR-126 in human cancers: Clinical roles and current perspectives. Exp Mol Pathol. 96:98–107. 2014. View Article : Google Scholar : PubMed/NCBI
9	Feng R, Chen X, Yu Y, Su L, Yu B, Li J, Cai Q, Yan M, Liu B and Zhu Z: miR-126 functions as a tumour suppressor in human gastric cancer. Cancer Lett. 298:50–63. 2010. View Article : Google Scholar : PubMed/NCBI
10	Crawford M, Brawner E, Batte K, Yu L, Hunter MG, Otterson GA, Nuovo G, Marsh CB and Nana-Sinkam SP: MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. Biochem Biophys Res Commun. 373:607–612. 2008. View Article : Google Scholar : PubMed/NCBI
11	Kumar S, Davra VE, Obr A, Geng KL, Wood T and Birge R: Crk adaptor protein promotes PD-L1 expression, EMT and immune evasion in a murine model of triple-negative breast cancer. Oncoimmunology. 7:e13761552017. View Article : Google Scholar : PubMed/NCBI
12	Tsuda M and Tanaka S: Roles for crk in cancer metastasis and invasion. Genes Cancer. 3:334–340. 2012. View Article : Google Scholar : PubMed/NCBI
13	Yang J, Lan H, Huang X, Liu B and Tong Y: MicroRNA-126 inhibits tumor cell growth and its expression level correlates with poor survival in non-small cell lung cancer patients. PLoS One. 7:e429782012. View Article : Google Scholar : PubMed/NCBI
14	Sun X, Liu Z, Yang Z, Xiao L, Wang F, He Y, Su P, Wang J and Jing B: Association of microRNA-126 expression with clinicopathological features and the risk of biochemical recurrence in prostate cancer patients undergoing radical prostatectomy. Diagn Pathol. 8:2082013. View Article : Google Scholar : PubMed/NCBI
15	Song L, Xie X, Yu S, Peng F and Peng L: MicroRNA-126 inhibits proliferation and metastasis by targeting pik3r2 in prostate cancer. Mol Med Rep. 13:1204–1210. 2016. View Article : Google Scholar : PubMed/NCBI
16	Duffy MJ, McKiernan E, O'Donovan N and McGowan PM: Role of ADAMs in cancer formation and progression. Clin Cancer Res. 15:1140–1144. 2009. View Article : Google Scholar : PubMed/NCBI
17	Josson S, Anderson CS, Sung SY, Johnstone PA, Kubo H, Hsieh CL, Arnold R, Gururajan M, Yates C and Chung LW: Inhibition of ADAM9 expression induces epithelial phenotypic alterations and sensitizes human prostate cancer cells to radiation and chemotherapy. Prostate. 71:232–240. 2011. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Nalla AK, Estes N, Patel J and Rao JS: N-cadherin mediates angiogenesis by regulating monocyte chemoattractant protein-1 expression via PI3K/Akt signaling in prostate cancer cells. Exp Cell Res. 317:2512–2521. 2011. View Article : Google Scholar : PubMed/NCBI
20	Agostini M, Pucciarelli S, Calore F, Bedin C, Enzo M and Nitti D: miRNAs in colon and rectal cancer: A consensus for their true clinical value. Clin Chim Acta. 411:1181–1186. 2010. View Article : Google Scholar : PubMed/NCBI
21	Tian L, Fang YX, Xue JL and Chen JZ: Four microRNAs promote prostate cell proliferation with regulation of PTEN and its downstream signals in vitro. PLoS One. 8:e758852013. View Article : Google Scholar : PubMed/NCBI
22	Kopczyńska E: Role of microRNAs in the resistance of prostate cancer to docetaxel and paclitaxel. Contemp Oncol (Pozn). 19:423–427. 2015.PubMed/NCBI
23	Nath D, Slocombe PM, Webster A, Stephens PE, Docherty AJ and Murphy G: Meltrin gamma(ADAM-9) mediates cellular adhesion through alpha(6)beta(1)integrin, leading to a marked induction of fibroblast cell motility. J Cell Sci. 113:2319–2328. 2000.PubMed/NCBI
24	Lendeckel U, Kohl J, Arndt M, Carl-McGrath S, Donat H and Röcken C: Increased expression of ADAM family members in human breast cancer and breast cancer cell lines. J Cancer Res Clin Oncol. 131:41–48. 2005. View Article : Google Scholar : PubMed/NCBI
25	Shintani Y, Higashiyama S, Ohta M, Hirabayashi H, Yamamoto S, Yoshimasu T, Matsuda H and Matsuura N: Overexpression of ADAM9 in non-small cell lung cancer correlates with brain metastasis. Cancer Res. 64:4190–4196. 2004. View Article : Google Scholar : PubMed/NCBI
26	Mazzocca A, Coppari R, De Franco R, Cho JY, Libermann TA, Pinzani M and Toker A: A secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal interactions. Cancer Res. 65:4728–4738. 2005. View Article : Google Scholar : PubMed/NCBI
27	Kim JM, Jeung HC, Rha SY, Yu EJ, Kim TS, Shin YK, Zhang X, Park KH, Park SW, Chung HC and Powis G: The effect of disintegrin-metalloproteinase ADAM9 in gastric cancer progression. Mol Cancer Ther. 13:3074–3085. 2014. View Article : Google Scholar : PubMed/NCBI
28	Fry JL and Toker A: Secreted and membrane-bound isoforms of protease ADAM9 have opposing effects on breast cancer cell migration. Cancer Res. 70:8187–8198. 2010. View Article : Google Scholar : PubMed/NCBI
29	Itabashi H, Maesawa C, Oikawa H, Kotani K, Sakurai E, Kato K, Komatsu H, Nitta H, Kawamura H, Wakabayashi G and Masuda T: Angiotensin II and epidermal growth factor receptor cross-talk mediated by a disintegrin and metalloprotease accelerates tumor cell proliferation of hepatocellular carcinoma cell lines. Hepatol Res. 38:601–613. 2008. View Article : Google Scholar : PubMed/NCBI
30	Hirao T, Nanba D, Tanaka M, Ishiguro H, Kinugasa Y, Doki Y, Yano M, Matsuura N, Monden M and Higashiyama S: Overexpression of ADAM9 enhances growth factor-mediated recycling of E-cadherin in human colon cancer cell line HT29 cells. Exp Cell Res. 312:331–339. 2006.PubMed/NCBI
31	Mahimkar RM, Visaya O, Pollock AS and Lovett DH: The disintegrin domain of ADAM9: A ligand for multiple beta1 renal integrins. Biochem J. 385:461–468. 2005. View Article : Google Scholar : PubMed/NCBI
32	Demirkan BM: The roles of epithelial-to-mesenchymal transition (EMT) and mesenchymal-to-epithelial transition (MET) in breast cancer bone metastasis: Potential targets for prevention and treatment. J Clin Med. 2:264–282. 2013. View Article : Google Scholar : PubMed/NCBI
33	Xie Y, Liu S, Lu W, Yang Q, Williams KD, Binhazim AA, Carver BS, Matusik RJ and Chen Z: Slug regulates E-cadherin repression via p19Arf in prostate tumorigenesis. Mol Oncol. 8:1355–1364. 2014. View Article : Google Scholar : PubMed/NCBI
34	Cui Y and Yamada S: N-cadherin dependent collective cell invasion of prostate cancer cells is regulated by the N-terminus of α-catenin. PLoS One. 8:e550692013. View Article : Google Scholar : PubMed/NCBI